Hôpital Bichat-Claude Bernard

Paris, Île-de-France Region 75877

0 studies enrolling now · 6 studies all time

What they study most

Adjuvant, Angina Pectoris, Coronary Artery Disease, EGFR, Early Stage Lung Cancer, Exon 20, Hepatitis C, Chronic, Idiopathic Pulmonary Fibrosis, Lung Cancer, NSCLC, Stage IB-IIIA, Non-small Cell Lung Cancer, Post-surgical

Studies at this site

• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy — Stopped early
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) — Completed